Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CET
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
12/02 MERCK & CO., INC (NYSE : MRK) Gets Coveted Approval For Keytruda
12/02 Pharma execs weigh in on possible changes under Trump
12/01 MERCK : Global Protein Labeling Market is expected to grow at a CAGR of 12.2 % d..
12/01 MERCK : FDA Grants Priority Review to Supplemental Biologics License Application..
11/30 MERCK : New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Confere..
11/29 MERCK : Declares Dividend of $0.4700.
11/29 MERCK : Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Tho..
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
11/28 MERCK : FDA Grants Priority Review to Merck’s Supplemental Biologics Licen..
11/28DJAmazon Broadens Cloud Services as Big Companies Sign On
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:43a December 2016's 10 Worst CCC Stocks At Various Market Caps
12/03 Barron's searches for value in its top stock picks for 2017
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/01 The Big Gamble
12/01 WisdomTree Equity Income ETF (DHS) November Summary
Advertisement
Financials ($)
Sales 2016 39 888 M
EBIT 2016 13 690 M
Net income 2016 5 904 M
Debt 2016 4 610 M
Yield 2016 3,03%
P/E ratio 2016 29,45
P/E ratio 2017 18,46
EV / Sales 2016 4,34x
EV / Sales 2017 4,32x
Capitalization 168 544 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.85%168 544
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
SANOFI-4.20%103 510
More Results